Psyence Biomedical Ltd (PBM) Stock Analysis
Verdict: AVOID
A pre-revenue clinical lottery with a <12-month cash runway; survival depends entirely on Phase IIb data or aggressive dilutive financing.
Investment score: 22/100
Analysis as of
Is Psyence Biomedical Ltd stock worth reviewing? The TradeMates thesis
Avoid due to extreme dilution risk and imminent cash exhaust.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 10/100 (weight 15%)
- Earnings Quality: 5/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 20/100 (weight 10%)
- Risk-Adjusted Return: 35/100 (weight 15%)
Psyence Biomedical Ltd opportunities and risks
What speaks for PBM
- Niche Market Focus
What speaks against PBM
- Imminent Funding Gap/Dilution
Frequently asked questions about Psyence Biomedical Ltd (PBM)
Is PBM stock a good investment?
The TradeMates model rates Psyence Biomedical Ltd as AVOID with an investment score of 22/100. Avoid due to extreme dilution risk and imminent cash exhaust. This is algorithmic model output, not personal investment advice.
Is PBM stock a buy?
The TradeMates model verdict for PBM is AVOID with an investment score of 22/100. Treat this as a model signal to review, not a personal buy recommendation.